chronic rhinosinusitis pipeline insight

DelveInsight’s, “Chronic Rhinosinustis - Pipeline Insight, 2025,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Chronic Rhinosinustis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Rhinosinustis Understanding

Chronic Rhinosinustis: Overview

Rhinosinusitis is defined as inflammation of the mucosal linings of the nasal passage and paranasal sinuses. Chronic rhinosinusitis occurs when symptoms lasts longer than 12 weeks. The symptoms of chronic rhinosinusitis include nasal inflammation, facial pain/pressure, hyposmia/anosmia, nasal congestion, loss of sense of smell and sleep difficulties, and discolored nasal drainage. Chronic rhinosinusitis is diagnosed clinically with a physical examination and focused sinonasal history, including chronic rhinosinusitis, associated comorbidities and family history. The treatment for chronic rhinosinusitis is focused at enhancing mucociliary clearance, improving sinus drainage/outflow, eradicating local infection and inflammation, and improving access for topical medications. First-line treatment is nasal saline irrigation and intranasal corticosteroid sprays.

 

"Chronic Rhinosinustis - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Rhinosinustis pipeline landscape is provided which includes the disease overview and Chronic Rhinosinustis treatment guidelines. The assessment part of the report embraces, in depth Chronic Rhinosinustis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Rhinosinustis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Rhinosinustis R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Rhinosinustis.

Chronic Rhinosinustis Emerging Drugs Chapters

This segment of the Chronic Rhinosinustis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Chronic Rhinosinustis Emerging Drugs

CBP-201: Connect Biopharma

CBP-201 is a human monoclonal antibody targeting IL-4Rα, which we have observed to have dose-dependent and differentiated pharmacokinetics and pharmacodynamics in an early clinical trial. Preclinical and clinical data demonstrate that dual inhibition of IL-4 and IL-13 dual is required to achieve desired efficacy in Th2-mediated diseases. CBP-201 binds to IL-4Rα in a manner that prevents the receptor from interacting with other receptor subunits that are required for activation of the signaling pathways that ultimately give rise to Th2-mediated diseases, including atopic dermatitis, asthma and nasal polyps. Currently, it is in Phase II stage of clinical trial evaluation to treat Chronic Rhinosinusitis With Nasal Polyps

 

LYR-210: Lyra Therapeutics

Lyra’s lead product candidate, LYR-210, has completed Phase 2 clinical development to treat chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses. LYR-210 is an anti-inflammatory implantable drug matrix based upon Lyra’s XTreo™ platform designed to elute mometasone furoate consistently and locally to the inflamed mucosal tissue of CRS patients for up to six months from a single treatment. LYR-210 is being developed as an alternative to sinus surgery for CRS patients.

Further product details are provided in the report……..

Chronic Rhinosinustis: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Rhinosinustis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Chronic Rhinosinustis

There are approx. 6+ key companies which are developing the therapies for Chronic Rhinosinustis. The companies which have their Chronic Rhinosinustis drug candidates in the most advanced stage, i.e. Phase II include, Lyra Therapeutics.

Phases

DelveInsight’s report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Chronic Rhinosinustis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Rhinosinustis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic Rhinosinustis therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Rhinosinustis drugs.

Chronic Rhinosinustis Report Insights

• Chronic Rhinosinustis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Rhinosinustis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Rhinosinustis drugs?
• How many Chronic Rhinosinustis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Rhinosinustis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Rhinosinustis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Rhinosinustis and their status?
• What are the key designations that have been granted to the emerging drugs?